Keith Murphy is the co-founder, Chairman, and CEO of Organovo and is also Chairman and co-founder of the non-profit Human Organ Project.
San Diego based Organovo is changing the shape of medical research and practice using the world’s premier 3D bioprinting technology to create liver, kidney, and other organ tissues for use in research and transplantation. Mr. Murphy is the co-inventor of the Novogen MMX, Organovo’s bioprinting platform and the world’s first commercial bioprinter. Organovo has developed advanced liver and kidney tissues and is partnered with world beauty industry leader L’Oréal on the development of 3D bioprinted skin. The company released its exVive3D Human Liver tissue, the world’s first bioprinted tissue product, in November 2014.
The Human Organ Project (HOP) raises private contributions towards funding cutting edge medical research in the creation of new human organ tissues for transplant. HOP is partnered with the American Society of Transplantation (AST) to award research grants that drive critical basic research and translational scientific steps forward for the field of de novo organ creation.
Mr. Murphy has more than 23 years of experience in biotechnology, including being responsible for all company operations of Organovo since its founding in 2007 and serving various executive leadership roles at Amgen. His ten years at Amgen included four years as Global Operations Leader for the largest development program in Amgen’s history, denosumab, now marketed as Prolia for osteoporosis and Xgeva for cancer indications. At Amgen he also worked in a technical executive leadership role, leading teams developing several other novel formulation and device products. Prior to Amgen, he worked at biotech Alkermes during its startup years, where he helped develop the company’s first approved product, Nutropin (hGH) Depot, developed in partnership with Genentech. Mr. Murphy serves as a Board member of the Torrance Memorial Medical Center Healthcare Foundation, and is a former Vice Chairman of the Alliance for Regenerative Medicine, a coalition of industry, academia, patient advocates and other groups dedicated to the advancement of regenerative medicine. He holds a B.S. in chemical engineering from the Massachusetts Institute of Technology and is an alumnus of the UCLA Anderson School of Management.